Ribomic's achondroplasia drug shows sustained growth in trial

Ribomic announced sustained efficacy of umedaptanib pegol in achondroplasia patients, showing increased growth rates over 1.5 years.

Two pediatric patients in a Phase IIa trial experienced notable improvements, with annualized height growth exceeding Voxzogo's average. No safety concerns have been reported.